Loading...
Loading...
Abbott
today
announced that it has initiated the ABSORB Japan randomized controlled
clinical trial to evaluate the Absorb™ Bioresorbable Vascular Scaffold (BVS)
in patients with coronary artery disease (CAD), the most common form of heart
disease.^1 The results of this trial will support regulatory filings with the
Japanese Pharmaceutical and Medical Devices Agency (PMDA) for approval of
Absorb BVS in Japan.
The Absorb BVS, a drug eluting, fully bioresorbable vascular scaffold, is a
small mesh tube designed to open a blocked heart vessel, restore blood flow to
the heart and then dissolve into the vessel over time.^2 Unlike a metallic
stent that remains permanently in the body, Absorb is referred to as a
scaffold to indicate that it is a temporary structure. Abbott's Absorb is made
of polylactide, a naturally dissolvable material that is commonly used in
medical implants such as dissolving sutures.
CAD is the leading cause of death in the world.^3 In Japan, changes in diet
and lifestyle have raised concerns of a potential increase in heart
disease-related deaths.^4 According to the World Health Organization (WHO),
cardiovascular disease is responsible for nearly one-third of all deaths in
Japan.^5
ABSORB Japan will enroll approximately 400 patients and compare the
performance of Absorb to Abbott's market-leading XIENCE™ family of metallic
drug eluting stents. The primary endpoint is target lesion failure (TLF) at
one year, a combined measure of safety and efficacy of the device. Takeshi
Kimura, M.D., professor, Department of Cardiovascular Medicine, Kyoto
University Hospital, is the principal investigator of the ABSORB Japan trial.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in